Literature DB >> 6831399

Experimental antitumor activity and toxicity of a new chemotherapeutic agent, BBM 928A.

W C Rose, J E Schurig, J B Huftalen, W T Bradner.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6831399

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  6 in total

1.  Phase II trial of echinomycin in advanced colorectal cancer. A Southwest Oncology Group study.

Authors:  T D Brown; P J Goodman; T R Fleming; S A Taylor; J S Macdonald
Journal:  Invest New Drugs       Date:  1991-02       Impact factor: 3.850

2.  Echinomycin decreases induction of vascular endothelial growth factor and hepatocyte regeneration in acetaminophen toxicity in mice.

Authors:  Alessandra Milesi-Hallé; Sandra McCullough; Jack A Hinson; Richard C Kurten; Laura W Lamps; Aliza Brown; Laura P James
Journal:  Basic Clin Pharmacol Toxicol       Date:  2011-11-09       Impact factor: 4.080

3.  Preclinical antitumor activity of a soluble etoposide analog, BMY-40481-30.

Authors:  W C Rose; G A Basler; P A Trail; M Saulnier; A R Crosswell; A M Casazza
Journal:  Invest New Drugs       Date:  1990       Impact factor: 3.850

4.  Experimental antitumor activity of BMY-28175 a new fermentation derived antitumor agent.

Authors:  J E Schurig; W C Rose; H Kamei; Y Nishiyama; W T Bradner; D A Stringfellow
Journal:  Invest New Drugs       Date:  1990-02       Impact factor: 3.850

5.  Korkormicins, novel depsipeptide antitumor antibiotics from Micromonospora sp C39500: fermentation, precursor directed biosynthesis and biological activities.

Authors:  K S Lam; D R Gustavson; G A Hesler; T T Dabrah; J A Matson; R L Berry; W C Rose; S Forenza
Journal:  J Ind Microbiol       Date:  1995-07

6.  Experimental antitumor activity of BMY-28090, a new antitumor antibiotic.

Authors:  J E Schurig; W T Bradner; G A Basler; W C Rose
Journal:  Invest New Drugs       Date:  1989-07       Impact factor: 3.850

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.